Selank
Tuftsin-based heptapeptide analog with anxiolytic and nootropic properties. Approved in Russia as an anxiolytic. Modulates GABA-A receptors and BDNF expression without dependency or sedation.
Selank is a synthetic heptapeptide derived from tuftsin — a natural tetrapeptide with immunomodulatory and psychotropic properties. Developed by the Russian Academy of Sciences, it is approved in Russia as an anxiolytic drug.
The anxiolytic mechanism involves modulation of GABA-A receptors without the dependency, tolerance, or sedation associated with benzodiazepines. Selank also demonstrates BDNF upregulation and serotonergic effects that contribute to its mood-stabilizing and cognitive properties.
In physician practice, Selank is typically paired with Semax. Semax provides stimulatory and BDNF-enhancing effects while Selank provides anxiolytic and calming effects — preventing overstimulation that can occur with Semax alone.
What are you researching?
Tell us your focus area and we’ll send a personalized research guide.
Selank is not FDA-approved. Research use only. Russian clinical literature reports favorable tolerability and no reported dependency. Western long-term safety data absent. Not WADA-prohibited. All information for educational reference only.